Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Endosomal Escape Vehicles to Enhance the Functional Delivery of Oligonucleotides in Preclinical Models of Neuromuscular Diseases
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 2022 International Conference on Muscle Wasting
- On: September 15, 2022
DownloadSeptember 15, 2022 -
Development of a Novel, EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: 7th International Myology Congress
- On: September 12, 2022
DownloadSeptember 12, 2022 -
EEV-Conjugated PMO Results in Nuclear Foci Reduction and Aberrant Splicing Correction in Myotonic Dystrophy Cell and Animal Models
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: https://srv1-front.key4events.com/?e=1336
- On: September 12, 2022
DownloadSeptember 12, 2022 -
Introduction to Entrada Therapeutics and the Endosomal Escape Vehicle (EEV™) Platform to Enhance Oligonucleotide Delivery in Myotonic Dystrophy Type 1
- By: Michael Oldham, MD, Executive Medical Director, Entrada Therapeutics
- At: 2022 Myotonic Dystrophy Foundation (MDF) Annual Conference
- On: September 10, 2022
DownloadSeptember 10, 2022 -
Endosomal Escape Vehicle (EEV) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: Parent Project Muscular Dystrophy (PPMD) 2022 Annual Conference
- On: June 24, 2022
DownloadJune 24, 2022